P-glycoprotein,multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir

Abstract

Background

Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypep-tide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular concentrations of some HIV protease inhibitors (HPIs). Here, we studied the lipophilicity and uptake of [³H]-atazanavir (ATV) in CEM (parental), CEM_VBL (P-gp-overexpressing), CEM_E1000 (MRP1-overexpressing) and peripheral blood mononuclear cells (PBMCs), and evaluate the effects of modulators of drug transporters on uptake.

Methods

Lipophilicity was measured by octanol/saline partition method. The influence of influx/efflux transporters on uptake was evaluated in the absence and presence of inhibitors of P-gp (GPV031), P-gp/BCRP (tariquidar and GF120918), P-gp/MRP1 (dipyrida-mole and daidzein), MRP1/2 (frusemide and genistein), hOATP/hOCTP (estrone-3-sulfate [E-3-S]) and hOATP/ hOCTP/MRP (probenecid). The effects of a number of HPIs on uptake were also evaluated. Data from digitonin permeabilized cells allowed the evaluation of the contribution of cellular binding to total drug uptake, whereas the inhibitory effect of ATV on P-gp was assessed by daunomycin efflux/uptake assays.

Results

[³H]-ATV is lipophilic and accumulates in the cultured cells as follows: CEM>CEM_E1000>CEM_VBL. Tariquidar, GF120918 and daidzein significantly increased the uptake of [³H]-ATV in the cultured cells. By contrast, only daidzein and tipranavir significantly increased uptake in PBMCs, with tariquidar and frusemide devoid of effects, whereas dipyridamole, E-3-S, GPV031 and genistein significantly decreased accumulation. ATV inhibits P-gp activity; manipulation of uptake with digitonin suggests binding of [³H]-ATV to P-gp.

Conclusions

[³H]-ATV is lipophilic, a P-gp, MRP and hOATP substrate and an inhibitor of P-gp. Concomitant administration of ATV with drugs and dietary components (for example, daidzein and genistein) that interact with these transporters could alter its pharmacokinetics.

References

Janneh

, Owen

, Chandler

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.

AIDS 2005; 19: 2097–2102.

Janneh

, Jones

, Chandler

, Owen

, Khoo

S.H.

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

J Antimicrob Chemother 2007; 60: 987–993.

Bousquet

, Roucairol

, Hembury

Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood–brain barrier.

AIDS Res Hum Retroviruses 2008; 24: 1147–1154.

, Zhang

, Sinko

P.J.

Human organic aniontransporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.

Mol Pharm 2004; 1: 49–56.

Zhang

, Gorset

, Washington

C.B.

, Blaschke

T.F.

, Kroetz

D.L.

, Giacomini

K.M.

Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.

Drug Metab Dispos 2000; 28: 329–334.

Janneh

, Hartkoorn

R.C.

, Jones

Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.

Br J Pharmacol 2008; 155: 875–883.

Izzedine

, Launay-Vacher

, Deray

Renal tubular transporters and antiviral drugs: an update.

AIDS 2005; 19: 455–462.

Huisman

M.T.

, Smit

J.W.

, Wiltshire

H.R.

, Hoetelmans

R.M.

, Beijnen

J.H.

, Schinkel

A.H.

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Mol Pharmacol 2001; 59: 806–813.

Park

, Sinko

P.J.

P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

J Pharmacol Exp Ther 2005; 312: 1249–1256.

10.

Kim

A.E.

, Dintaman

J.M.

, Waddell

D.S.

, Silverman

J.A.

Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.

J Pharmacol Exp Ther 1998; 286: 1439–1445.

11.

Lee

C.G.

, Gottesman

M.M.

, Cardarelli

C.O.

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Biochemistry 1998; 37: 3594–3601.

12.

Washington

C.B.

, Duran

G.E.

, Man

M.C.

, Sikic

B.I.

, Blaschke

T.F.

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.

J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203–209.

13.

Jones

, Bray

P.G.

, Khoo

S.H.

P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

AIDS 2001; 15: 1353–1358.

14.

Huisman

M.T.

, Smit

J.W.

, Crommentuyn

K.M.

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

AIDS 2002; 16: 2295–2301.

15.

Agarwal

, Pal

, Mitra

A.K.

Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor.

Int J Pharm 2007; 339: 139–147.

16.

Gutmann

, Fricker

, Drewe

, Toeroek

, Miller

D.S.

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

Mol Pharmacol 1999; 56: 383–389.

17.

Ronaldson

P.T.

, Lee

, Dallas

, Bendayan

Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.

Pharm Res 2004; 21: 811–818.

18.

Bachmeier

C.J.

, Spitzenberger

T.J.

, Elmquist

W.F.

, Miller

D. W.

. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 2005; 22: 1259–1268.

19.

Williams

G.C.

, Liu

, Knipp

, Sinko

P.J.

Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).

Antimicrob Agents Chemother 2002; 46: 3456–3462.

20.

Shiraki

, Hamada

, Yasuda

, Fujii

, Arimori

, Nakano

Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

Biol Pharm Bull 2000; 23: 1528–1531.

21.

Chandler

, Almond

, Ford

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.

J Acquir Immune Defic Syndr 2003; 33: 551–556.

22.

Dupuis

M.L.

, Flego

, Molinari

, Cianfriglia

Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.

HIV Med 2003; 4: 338–345.

23.

Storch

C.H.

, Theile

, Lindenmaier

, Haefeli

W.E.

, Weiss

Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

Biochem Pharmacol 2007; 73: 1573–1581.

24.

Gupta

, Zhang

, Unadkat

J.D.

, Mao

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

J Pharmacol Exp Ther 2004; 310: 334–341.

25.

Weiss

, Rose

, Storch

C.H.

Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

J Antimicrob Chemother 2007; 59: 238–245.

26.

Colombo

, Soranzo

, Rotger

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.

Pharmacogenet Genomics 2005; 15: 599–608.

27.

Wang

, Furukawa

, Nitanda

Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

Mol Pharmacol 2003; 63: 65–72.

28.

Hsu

, Granneman

G.R.

, Bertz

R.J.

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Clin Pharmacokinet 1998; 35: 275–291.

29.

Ford

, Boffito

, Maitland

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

J Antimicrob Chemother 2006; 58: 1009–1016.

30.

Perloff

E.S.

, Duan

S.X.

, Skolnik

P.R.

, Greenblatt

D.J.

, von Moltke

L.L.

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

Drug Metab Dispos 2005; 33: 764–770.

31.

Chinn

L.W.

, Gow

J.M.

, Tse

M.M.

, Becker

S.L.

, Kroetz

D.L.

Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.

J Antimicrob Chemother 2007; 60: 61–67.

32.

Pick

, Muller

, Wiese

Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).

Bioorg Med Chem 2008; 16: 8224–8236.

33.

Kuhnle

, Egger

, Muller

Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-glycoprotein (ABCB1) modulator tariquidar.

J Med Chem 2009; 52: 1190–1197.

34.

Mistry

, Stewart

A.J.

, Dangerfield

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Cancer Res 2001; 61: 749–758.

35.

Damle

B.D.

, Sridhar

, Desai

P.B.

Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells.

Int J Cancer 1994; 56: 113–118.

36.

Verstuyft

, Strabach

, El-Morabet

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.

Clin Pharmacol Ther 2003; 73: 51–60.

37.

Kawamura

, Yamasaki

, Yui

In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.

Nucl Med Biol 2009; 36: 239–246.

38.

Chiba

, Ecker

, Schmid

Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.

Mol Pharmacol 1996; 49: 1122–1130.

39.

Tahara

, Kusuhara

, Chida

, Fuse

, Sugiyama

Is the monkey an appropriate animal model to examine drug–drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.

J Pharmacol Exp Ther 2006; 316: 1187–1194.

40.

Sakamoto

, Mikami

, Kimura

Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Br J Pharmacol 2008; 154: 1482–1490.

41.

Jager

, Winter

, Halper

Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat.

Hepatology 1997; 26: 1467–1476.

42.

Bobrowska-Hagerstrand

, Wrobel

, Rychlik

Monitoring of MRP-like activity in human erythrocytes: inhibitory effect of isoflavones.

Blood Cells Mol Dis 2001; 27: 894–900.

43.

Evans

A.M.

Influence of dietary components on the gastrointestinal metabolism and transport of drugs.

Ther Drug Monit 2000; 22: 131–136.

44.

Cooray

H.C.

, Janvilisri

, van Veen

H.W.

, Hladky

S.B.

, Barrand

M.A.

Interaction of the breast cancer resistance protein with plant polyphenols.

Biochem Biophys Res Commun 2004; 317: 269–275.

45.

Wang

, Wolkoff

A.W.

, Morris

M.E.

Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators.

Drug Metab Dispos 2005; 33: 1666–1672.

46.

Nguyen

, Zhang

, Morris

M.E.

Effect of flavonoids on MRP1-mediated transport in Panc-1 cells.

J Pharm Sci 2003; 92: 250–257.

47.

Enokizono

, Kusuhara

, Sugiyama

Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.

Mol Pharmacol 2007; 72: 967–975.

48.

Hodges

, Yikilmaz

, Patterson

An iron regulatory-like protein expressed in Plasmodium falciparum displays aconitase activity.

Mol Biochem Parasitol 2005; 143: 29–38.

49.

Gibbs

J.E.

, Thomas

S.A.

The distribution of the anti-HIV drug, 2'3’-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.

J Neurochem 2002; 80: 392–404.

50.

Sanchez Mdel

, Lopez

, Velez

, Yamamura

P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.

Ethn Dis 2008; 18 Suppl 2: S2-60–64.

51.

Profit

, Eagling

V.A.

, Back

D.J.

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

AIDS 1999; 13: 1623–1627.

52.

Cremaschi

, Meyer

, Rossetti

, Botta

, Palestini

The nature of the neutral Na⁺-Cl(^-)-coupled entry at the apical membrane of rabbit gallbladder epithelium: I. Na⁺/H⁺, Cl^-/ HCO3- double exchange and Na⁺-Cl^- symport.

J Membr Biol 1987; 95: 209–218.

53.

Joiner

C.H.

, Jiang

, Claussen

W.J.

, Roszell

N.J.

, Yasin

, Franco

R.S.

Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells.

Blood 2001; 97: 3976–3983.

54.

Letschert

, Faulstich

, Keller

, Keppler

Molecular characterization and inhibition of amanitin uptake into human hepatocytes.

Toxicol Sci 2006; 91: 140–149.

55.

Smith

N.F.

, Acharya

M.R.

, Desai

, Figg

W.D.

, Sparreboom

Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.

Cancer Biol Ther 2005; 4: 815–818.

56.

Zhang

, Chando

T.J.

, Everett

D.W.

, Patten

C.J.

, Dehal

S.S.

, Humphreys

W.G.

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Drug Metab Dispos 2005; 33: 1729–1739.

57.

Lankisch

T.O.

, Moebius

, Wehmeier

Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

Hepatology 2006; 44: 1324–1332.

58.

Chen

, Lin

, Hu

Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model.

Cancer Chemother Pharmacol 2005; 55: 159–169.

59.

Versantvoort

C.H.

, Rhodes

, Twentyman

P.R.

Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds.

Br J Cancer 1996; 74: 1949–1954.

60.

Maubach

, Depypere

H.T.

, Goeman

Distribution of soy-derived phytoestrogens in human breast tissue and biological fluids.

Obstet Gynecol 2004; 103: 892–898.

61.

Bousquet

, Roucairol

, Hembury

AIDS Res Hum Retroviruses 2008; 24: 1147–1154.

62.

Campbell

S.D.

, de Morais

S.M.

, Xu

J.J.

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.

Chem Biol Interact 2004; 150: 179–187.

63.

McRae

M.P.

, Lowe

C.M.

, Tian

Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.

J Pharmacol Exp Ther 2006; 318: 1068–1075.